2023
Newly Designed Poxviral Promoters to Improve Immuogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.
Langenmayer M.C., Luelf-Averhoff A.T., Marr L., Jany S., Freudenstein A., Adam-Neumair S., Tscherne A., Fux R., Rojas J.J., Blutke A., Sutter G., Volz A.
Pathogens. 2023 Jun 23;12(7):867. doi: 10.3390/pathogens12070867. PMID: 37513714; PMCID10383309.
Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
Kalodimou G., Jany S., Freudenstein A., Schwarz J.H., Limpinsel L., Rohde C., Kupke A., Becker S., Volz A., Tscherne A., Sutter G.
Viruses. 2023 May 17;15(5):1180. doi:10.3390/v15051180. PMID: 37243266; PMCID: PMC10222707.
MERS-CoV-Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.
Meyer Zu Natrup C, Schünemann LM, Saletti G, Clever S, Herder V, Joseph S, Rodriquez M, Wernery U, Sutter G, Volz A.
Emerg Infect Dis. 2023 Jun;29(6):1236-1239. doi: 10.3201/eid2906.230128. PMID: 37209676.
Recombinant Modiefied Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice.
Wilken L., Stelz S., Agac A., Sutter G., Prajeeth C.K., Rimmelzwaan G.F.
Vaccines (Basel) 2023 Mar 23;11(4):714. doi: 10.3390/vaccines11040714
A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.
Kubinski M., Beicht J., Zdora I., Biermann J., Puff C., Gerlach T., Tscherne A., Baumgärtner W., Osterhaus A.D.M.E., Sutter G., Prajeeth C.K., Rimmelzwaan G.F.
Front Immunol. 2003 Apr 21;14:1182963. doi: 10.3389/fimmu.2023.1182963. eCollection 2023
Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease.
Riederer S., Canizo, A. del, Navas J., Peter M.G., Link E.K., Sutter G., Rojas J.J.
Cancer Gene Ther. 2023 Apr 4. doi: 10.1038/s41417-023-00610-5
Der Huchen stirbt aus - was tun? Gefährdungsfaktoren und notwendige Maßnahmen in Bayern und Österreich.
Schmutz S., Jungwirth M., Ratschan C., Siemens S. von, Guttmann S., ..., Sutter G., Schröder W., Zauner G.
Österreichs Fischerei, 76. Jahrgang Sonderausgabe 2023, https://www.fischerei-verband.at/themen/fisch-des-jahres/2023-hucher/
Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein.
Raadsen M.P., Dahlke C., Fathi A., Lamers M.M., Doel van den P., Zaeck L.M., Royen van M.E., Bruin de E., Sikkema R., Koopmans M., Gorp van E.C.M., Sutter G., Vries de R.D., Addo M.M., Haagmans B.L.
J Infect Dis. 2023 Mar 1;jiad052. https://doi.org/10.1093/infdis/jiad052
Direct intranodal tonsil vacination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac 251.
Mattathil J.G., Volz A., Onabajo O.O., Maynard S., Bixler S.L., Shen X.X., Vargas-Inchaustegui D., Robert-Guroff M., Lebranche C., Tomaras G., Montefiori D., Sutter G., Mattapallil J.J.
Nat Commun. 2023 Mar 7;14(1):1264. https://doi.org/10.1038/s41467-023-36907-0
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.
Sacherl J., Kosinska A.D., Kemter K., Kächele M., Laumen C.S., Kerth H.A., Öz E.A., Wolff L.S., Su J., Essbauer S., Sutter G., Scholz M., Singethan K., Altrichter J., Protzer U.
JHEP Rep. 2023 Feb; 5(2):100603. doi: 10.1016/j.jhepr.2022.100603